Crosstalk between S-nitrosylation and glycation defines a metabolic vulnerability in liver and renal cancers

Metabolic reprogramming is a hallmark of cancer, yet the specific mechanisms linking metabolic shifts to therapeutic resistance are not fully understood. This study investigates the role of aldo-ketoreductase 1A1 (AKR1A1) in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), exploring whether its loss contributes to aggressive tumor phenotypes and therapy resistance.

Using transcriptomic data from TCGA cohorts and various RCC and HCC cell models, the authors analyzed the metabolic consequences of AKR1A1 deficiency. They employed metabolic network reconstruction, stable isotope tracing, and CRISPR-Cas9 engineering to map the signaling axis connecting AKR1A1 loss to downstream metabolic and transcriptional changes. The study also tested the therapeutic potential of targeting the glyoxalase system—the primary pathway for detoxifying methylglyoxal (MGO)—in patient-derived cells and mouse xenograft models.

The researchers identified AKR1A1 as a metabolic tumor suppressor. Its loss disrupts terminal glycolytic flux by promoting the S-nitrosylation of pyruvate kinase M2 (PKM2), which inhibits its activity. This metabolic bottleneck leads to the accumulation of methylglyoxal (MGO). Elevated MGO triggers the autophagic degradation of Keap1, resulting in the activation of the NRF2 transcriptional program. This NRF2-driven response confers chemoresistance and promotes cell migration. Crucially, the study demonstrates that pharmacological inhibition of the glyoxalase system (using BBGC) creates a synthetic vulnerability, restoring drug sensitivity in AKR1A1-deficient tumor models.

These findings uncover a novel regulatory axis where S-nitrosylation and glycation crosstalk to drive tumor aggressiveness. By identifying AKR1A1 loss as a metabolic vulnerability, the study provides a potential precision medicine strategy: using glyoxalase inhibitors to re-sensitize resistant liver and renal cancers to standard chemotherapies.